Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma that is largely chemoresistant. Ibrutinib, a drug that inhibits Bruton’s tyrosine kinase (BTK), has improved the overall survival of patients with MCL; however, resistance to ibrutinib has emerged as a decisive, negative factor in the prognosis of MCL. Adopting a more patient-centric therapeutic approach that incorporates applied genomics and interrogation of B cell signaling pathways may offer an alternative route to reach durable remission in patients with MCL. Although targeting genetic variants in MCL is not yet feasible in the clinical setting, the identification and targeting of increasingly active B cell signaling pathways may be a viable therapeutic strategy that may improve patient outcomes. Genome-editing tools and sequencing platforms could play dominant roles in patient-centric approaches of treatment in the future, potentially improving clinical outcomes for patients with MCL.

套细胞淋巴瘤（MCL）是一种侵袭性B细胞淋巴瘤，在很大程度上具有化学抗性。依鲁替尼是一种抑制布鲁顿酪氨酸激酶（BTK）的药物，它改善了MCL患者的整体生存率。然而，对依鲁替尼的耐药性已成为MCL预后的决定性，负面因素。采用以患者为中心的治疗方法，结合应用的基因组学和对B细胞信号通路的询问，可能为MCL患者提供持久的缓解途径。尽管在临床环境中靶向MCL的遗传变异尚不可行，但鉴定和靶向日益活跃的B细胞信号通路可能是可行的治疗策略，可以改善患者的预后。